Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10306884" target="_blank" >RIV/00216208:11110/15:10306884 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10306884

Výsledek na webu

<a href="http://dx.doi.org/10.1056/NEJMoa1501481" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1501481</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1501481" target="_blank" >10.1056/NEJMoa1501481</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Popis výsledku v původním jazyce

BACKGROUND: Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders. METHODS: We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 mu g once weekly, for up to 144 weeks. The primary end point was the annualized relapse rate. CONCLUSIONS: Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as assessed by means of MRI, but was not associated with a significantly

Název v anglickém jazyce

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Popis výsledku anglicky

BACKGROUND: Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders. METHODS: We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 mu g once weekly, for up to 144 weeks. The primary end point was the annualized relapse rate. CONCLUSIONS: Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as assessed by means of MRI, but was not associated with a significantly

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

373

Číslo periodika v rámci svazku

15

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1418-1428

Kód UT WoS článku

000362372800008

EID výsledku v databázi Scopus

2-s2.0-84943562782